Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2022

BioPharm International

  • BioPharm International, February 2022
  • Volume 35
  • Issue 2
  • Pages: 40

Single-Use Separator

The GEA kytero combines the high performance of larger GEA stainless-steel pharmaceutical centrifuges with the benefits offered by disposable components.

The GEA kytero single-use separator, intended for use in fermentation solutions and cell cultures, is equipped with GEA Westfalia Separator disk stack technology designed for maximum yield, high separation efficiency, and gentle product handling.

The GEA kytero combines the high performance of larger GEA stainless-steel pharmaceutical centrifuges with the benefits offered by disposable components that do not require cleaning. The technology relies on centrifugal separation, rather than filter-based harvesting, for increased clarification efficiency.

To prevent cross-contamination and hygienic cell harvesting, all elements that come into contact with the product, such as hoses and containers, are made of recyclable material and are replaced after use. The design of the aseptic connector system is intended to ease the process of exchanging single-use components. The mobile plug & produce unit also fits into any cleanroom.

GEA
www.gea.com

Articles in this issue


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.